Drug intelligence / Profile preview

WoundaGel

Development stage: Preclinical
Lead developer: Remedor Biomed
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

**WoundaGel** is Remedor Biomed's proprietary topical biologic wound-healing product, delivered in a smart hydrogel matrix. It is being developed primarily as an adjunctive treatment for diabetic neuropathic foot ulcers, with additional pipeline applications in burn injuries and epidermolysis bullosa. The product's specific active constituent, molecular target, and defined molecular mechanism have not been publicly disclosed; its intended effect is to support wound repair and healing within a topical hydrogel-based delivery system. ([remedor.lav.megatam.com](https://remedor.lav.megatam.com/en/p11_products.html))

Brand names: WoundaGel
Other names: Topical erythropoietin hydrogelEPO hydrogelrecombinant human erythropoietin hydrogel

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on WoundaGel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WoundaGel.

Explore the full profile